Please login to the form below

Not currently logged in
Email:
Password:

Dr Malte Peters joins MorphoSys

He succeeds Dr Arndt Schottelius as chief development officer

MorphoSys Dr Malte PetersGermany-based therapeutic antibodies specialist MorphoSys has appointed Dr Malte Peters as its new chief development officer, succeeding Dr Arndt Schottelius from 1 March.

Dr Peters joins MorphoSys from Sandoz, where he served as global head of clinical development in its biopharmaceuticals business unit.

Prior to this, he was Novartis' clinical head of oncology translational medicine and head of its Basel and East Hanover sites, and served as head of translational research and pharmacogenomics at Merck KGaA.

During this time he also held teaching appointments in internal medicines and biochemistry at the University of Mainz, in Germany.

Dr Gerald Möller, chairman of MorphoSys' supervisory board, said: “Dr Peters is an ideal addition to the management board of MorphoSys at this stage of the company's growth.

“Drawing on his deep operational and medical experience in oncology and immunology, he will focus his efforts on the development of our clinical and pre-clinical programmes, the most valuable assets driving out future growth.”

17th January 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics